How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,755 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Advanced-stage Mycosis Fungoides. Role of STAT3, NFKB and NFAT pathways. (PubMed)

Advanced-stage Mycosis Fungoides. Role of STAT3, NFKB and NFAT pathways. The malignant mechanisms that control the development of cutaneous T-cell lymphoma (CTCL) are beginning to be identified. Recent evidence suggests that disturbances in specific intracellular signalling pathways, such as RAS-MAPK, TCR-PLCG1-NFAT and JAK-STAT, may play an essential role in the pathogenesis of CTCL.We collected 100 samples that were submitted for diagnosis of, or a second opinion regarding mycosis fungoides

2019 British Journal of Dermatology

22. Special Considerations in the Treatment of Mycosis Fungoides. (PubMed)

Special Considerations in the Treatment of Mycosis Fungoides. Mycosis fungoides is the most common form of cutaneous T cell lymphoma. Although normally presenting to physicians at an early stage and with an indolent course, mycosis fungoides can have a varied presentation. The National Comprehensive Cancer Network (NCCN) has created guidelines for the treatment and staging of mycosis fungoides. Although comprehensive, in practice these guidelines do not provide specific treatment regimens (...) the possibility of side effects. Additionally, lesions located in the bathing suit distribution are often nonresponsive to first-line therapies for reasons still undetermined. Finally, although well-described, erythroderma secondary to mycosis fungoides is challenging to treat, with controversy surrounding various methods of control. This article both highlights difficult clinical scenarios and reviews the recommended treatment as provided by the NCCN guidelines and provides alternative therapy for lesions

2019 American journal of clinical dermatology

23. Bexarotene as maintenance treatment after other than skin-directed therapy in advanced stage mycosis fungoides: a pilot study. (PubMed)

Bexarotene as maintenance treatment after other than skin-directed therapy in advanced stage mycosis fungoides: a pilot study. Advanced-stage mycosis fungoides (MF) and Sézary Syndrome (SS) patients have a poor quality of life and quickly relapse irrespective of the administered treatment. Most of the available therapies do not warrant long-lasting remission. In the last ten years, the need for an MF maintenance treatment has been investigated in the literature, with most of experiences

2019 Journal of the European Academy of Dermatology and Venereology

24. Epidemiological, clinical, histological, and immunohistochemical study on hypopigmented epitheliotropic T-cell dyscrasia and hypopigmented mycosis fungoides. (PubMed)

Epidemiological, clinical, histological, and immunohistochemical study on hypopigmented epitheliotropic T-cell dyscrasia and hypopigmented mycosis fungoides. Hypopigmented dermatoses, more evident in dark-skinned people, are a frequent cause of consultation. Their etiology includes a wide range of dermatoses, from benign to malignant diseases. The clinical presentation appears very similar between them, making the correct diagnoses and management a challenge.Clinical records (...) and histopathological biopsies were identified and compared in patients of the "Dr. Manuel Gea González" General Hospital throughout a 16-year period with the presumptive diagnosis of hypopigmented epitheliotropic T-cell dyscrasia (HTCD) or hypopigmented mycosis fungoides (HMF). Immunostaining analysis was performed in each specimen, the panel of antibodies used was: CD3, CD4, CD7, CD8, CD20, and CD62L.Thirty cases of 81 patients found in the registries were included in this study. The main age group was formed

2019 International Journal of Dermatology

25. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. (PubMed)

Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of T-cell neoplasms involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).The diagnosis of MF or SS requires the integration of clinical and histopathologic data.TNMB (tumor, node, metastasis, blood) staging remains the most important prognostic factor in MF/SS and forms the basis

2019 American journal of hematology

26. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. (PubMed)

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).CITN-10 is a single-arm, multicenter phase II trial of 24 patients with advanced MF or SS. Patients were treated with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months. The primary end point was overall response rate by consensus global response

2019 Journal of Clinical Oncology

27. Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression. (PubMed)

Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression. Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma1 . The clinical course is usually slow and the initial treatment is a skin-directed therapy2,3 . When MF becomes refractory, systemic therapies are needed2,3 . Disease progression is seen in about 30% of MF patients but no undisputable markers are available to identify these patients2,3 . Twist, Zeb1 and Slug are transcription

2019 Journal of the European Academy of Dermatology and Venereology

28. Regression of Mycosis Fungoides with Large Cell Transformation Following Skin Biopsy. (PubMed)

Regression of Mycosis Fungoides with Large Cell Transformation Following Skin Biopsy. Cutaneous T-cell lymphomas (CTCLs) are a group of mature extranodal T-cell lymphomas, of which mycosis fungoides (MF) is the most common subtype. MF commonly presents as patch-or-plaques on non-sun exposed areas of the body and often follows an indolent clinical course (1). Advanced MF, stage IIb-IV, has a 5-year survival which ranges from 28 to 68%. (2) Large cell transformation (LCT), age greater than 60

2019 Journal of the European Academy of Dermatology and Venereology

29. Exploratory Assessment Of Oxygen Flow Assisted Cutaneous Administration Of Methotrexate For Superficial Basal Cell Carcinoma, Mycosis Fungoides And Extramammary Paget's Disease. (PubMed)

Exploratory Assessment Of Oxygen Flow Assisted Cutaneous Administration Of Methotrexate For Superficial Basal Cell Carcinoma, Mycosis Fungoides And Extramammary Paget's Disease. The molecular weight of methotrexate (MTX) makes cutaneous penetration difficult. Oxygen flow could enhance the skin permeation of MTX diluted in the LP3 carrier system. This pilot study aims to assess the efficacy, safety and tolerance of oxygen-flow-administered (OFA)-LP3-MTX3% for treating superficial skin cancers (...) . Patients with superficial basal cell carcinoma (sBCC)(n=12), extramammary Paget's disease (EMPD)(n=5), mycosis fungoides classic type (CMF) (n=10) and folliculotropic (FMF) (n=6) were included in the study and were treated with 4 weekly applications of OFA-LP3-MTX3%. Photographs and biopsies were performed before (T0) and one month after treatment (T1). At T1, the mean sBCC ECT and EMPD EOSP clinical scores, and the modified CAILS CMF and FMF scores were improved by 77.5±17.1% (p<0.0001), 66.7±22.9% (p

2019 Journal of Investigative Dermatology

30. SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-κB pathway in Mycosis Fungoides. (PubMed)

SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-κB pathway in Mycosis Fungoides. Mycosis Fungoides (MF) is the most common subtype of cutaneous T-cell lymphomas (CTCL). Shank-associated RH domain-interacting protein (SHARPIN) participates in the initiation and development of multiple tumors. However, the clinical significance of SHARPIN in MF hasn't been investigated. The c-Jun N-terminal kinases (JNKs) pathway is a member of mitogen-activated protein kinases (MAPKs

2019 Experimental Dermatology

31. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: a Surveillance, Epidemiology, and End Results analysis. (PubMed)

Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: a Surveillance, Epidemiology, and End Results analysis. Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.We performed

2019 Journal of American Academy of Dermatology

32. Outcomes and Prognostic Factors In African American / Black Patients With Mycosis Fungoides And Sézary Syndrome: Retrospective Analysis Of 157 Patients From A Referral Cancer Center. (PubMed)

Outcomes and Prognostic Factors In African American / Black Patients With Mycosis Fungoides And Sézary Syndrome: Retrospective Analysis Of 157 Patients From A Referral Cancer Center. The prevalence of mycosis fungoides / Sézary syndrome (MF/SS) is higher in the African American (AA)/black population compared to Caucasians in the United States and worse outcomes have been observed in AA/black patients.To describe the outcomes and to identify prognostic factors in AA/black patients with MF

2019 Journal of American Academy of Dermatology

33. Poikilodermatous Mycosis Fungoides: Comparative Study of Clinical, Histopathological and Immunohistochemical Features. (PubMed)

Poikilodermatous Mycosis Fungoides: Comparative Study of Clinical, Histopathological and Immunohistochemical Features. Poikilodermatous mycosis fungoides (pMF) is characterized by poikiloderma areas, typically involving the major flexural areas and trunk. Its presentation can be generalized or admixed with other forms of MF. Previous studies fail to correlate the clinical presentation with prognosis and laboratory findings. Some reports show pityriasis lichenoides chronica (PLC) preceding

2019 Dermatology

34. Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial. (PubMed)

Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial. Background: Mycosis fungoides is the most common type of primary cutaneous T cell lymphomas. Doxycycline promoted apoptosis in different human malignant cell lines and in vivo models. Objectives: To test for the therapeutic efficacy of doxycycline in comparison to PUVA in early stages of classic MF and its effect on T cell apoptosis. Methods: Thirty-six patients were randomized

2019 Journal of Dermatological Treatment

35. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome. (PubMed)

The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome. It is difficult to distinguish erythrodermic mycosis fungoides from Sézary syndrome due to their similar clinical and histological features. The main purpose of this study was to investigate whether microRNA expression profiles in lesional skin could discriminate patients with erythrodermic mycosis fungoides from those with Sézary syndrome. A further aim was to assess whether the microRNA (...) expression profiles in erythrodermic mycosis fungoides skin was more comparable to microRNA expression profiles of Sézary syndrome or early-stage mycosis fungoides. RNA was extracted from diagnostic skin biopsies, followed by quantitative reverse transcription polymerase chain reaction analysis of 383 microRNAs. Twenty-seven microRNAs were significantly differentially expressed between erythro-dermic mycosis fungoides and Sézary syndrome. More-over, erythrodermic mycosis fungoides showed microRNA

2019 Acta Dermato-Venereologica

36. A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. (PubMed)

A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. 31512229 2019 10 14 1365-2133 2019 Sep 12 The British journal of dermatology Br. J. Dermatol. A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. 10.1111/bjd.18522 Papps T T Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Medical Oncology, University of Melbourne

2019 British Journal of Dermatology

37. Revisiting the initial diagnosis and blood staging of Mycosis Fungoides and Sézary Syndrome with the KIR3DL2 marker. (PubMed)

Revisiting the initial diagnosis and blood staging of Mycosis Fungoides and Sézary Syndrome with the KIR3DL2 marker. The early diagnosis of Sézary syndrome is challenging. Loss of CD7 and CD26 expression on CD4 T cells is currently used criteria in the initial diagnosis and staging of Sézary patients.Our goal was to evaluate the respective value of CD26, CD7 and KIR3DL2 expression on CD4+ T-cells and total lymphocytes at initial diagnosis of Sézary syndrome.This prospective study included 254

2019 British Journal of Dermatology

38. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome. (PubMed)

FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome. The FDA-approved mogamulizumab-kpkc, a CC chemokine receptor type 4 (CCR4)-directed mAb, in August 2018 for treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. Regular approval was based on a randomized, open-label trial that randomized 372 such patients, with a median of 3 prior systemic therapies, to either mogamulizumab-kpkc

2019 Clinical Cancer Research

39. Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version

Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer (...) Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: September 7, 2017. This PDQ cancer information summary has current information about the treatment of mycosis fungoides (including Sézary Syndrome). It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health

2017 PDQ - NCI's Comprehensive Cancer Database

40. Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma

Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/CHMP/13156/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) purified HPRT hypoxanthine-guanine phosphoribosyltransferase IARC International Agency for Research on Cancer IC50 half-maximal inhibitory concentration ICH International Conference on Harmonisation IID Inactive Ingredient Database i.p. intraperitoneal i.v. intravenous IR InfraredKF Karl Fischer titration LD50 median lethal dose MDA malondialdehyde MDEA N-methyldiethanolamine MF mycosis fungoides MF-type CTC mycosis fungoides-type cutaneous T-cell lymphoma MNNG N-methyl-N´-nitro-N-nitrosoguanidine MTD

2017 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>